BASF has acquired Equateq, a manufacturer of highly concentrated omega-3 fatty acids, for the pharmaceutical industry.
With the acquisition, BASF will offer highly concentrated omega-3 fatty acids for pharmaceutical and dietary supplement industries.
BASF Nutrition & Health division president Walter Dissinger said, "We are further strengthening our position as a leading supplier of ingredients for the nutrition and health industries."
Equateq has a production facility in Scotland with 47 employees.
Equateq will be integrated into the Pharma Ingredients & Services unit, which is part of BASF's Nutrition & Health division, which is expected to be completed by the end of 2012.
The financial details of the transaction were not disclosed by the companies.
BASF Pharma Ingredients &Services senior vice president Martin Widmann said, "Equateq's technologies will enable us to customize fatty acid concentrates with variable ratios of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) at concentration levels of up to 99 percent purity."
